Agenda: The Endocrinologic and Metabolic Drugs and the Drug Safety and Risk Management Advisory Committees will meet in joint session to discuss the cardiovascular ischemic/thrombotic risks of the thiazolidinediones, with focus on rosiglitazone, as presented by FDA and GlaxoSmithKline.
Location: Holiday Inn Gaithersburg, Two Montgomery Village Ave., Gaithersburg, Md.
Hotel phone number: 301-948-8900.
Contact Person:
Cathy A. Miller
Center for Drug Evaluation and
Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for
express delivery, 5630 Fishers Lane, rm. 1099), Rockville, MD 20857
Phone number: 301-827-7001, FAX: 301-827-6776
E-mail: Cathy.Miller1@fda.hhs.gov, or
For up-to-date information on this meeting:
1-800-741-8138 (301-443-0572 in the Washington, DC area), codes 3014512536 and 3014512535.
For more information, read the meeting announcement.